Genzyme Transgenics to Release First Quarter Financial Results Friday, April 20, 2001

Apr 17, 2001, 01:00 ET from Genzyme Transgenics Corporation

    FRAMINGHAM, Mass., April 17 /PRNewswire/ --
 Genzyme Transgenics (Nasdaq: GZTC) today said that its first quarter 2001
 financial results will be released on Friday, April 20, 2001, before the
 Nasdaq market opens.
     At 11:00 a.m. Eastern Time, as part of the Company's efforts to ensure
 full disclosure to all parties, Genzyme Transgenics will webcast a conference
 call with financial analysts live on the Company's internet site. This
 discussion is expected to include updates on the Company's many partnered
 programs. Dr. Sandra Nusinoff Lehrman, President and Chief Executive Officer,
 will lead the call. To access the live call or the archive, log onto
 http://www.transgenics.com. Please connect to the Company's website prior to
 the conference call to ensure adequate time for any software download that may
 be needed to hear the webcast.
     Genzyme Transgenics Corporation is a leader in developing medicines from
 the milk of specially bred animals, primarily goats. Many of the medicines
 under development are monoclonal antibodies and immunoglobulin fusion
 proteins. To date, GTC has formed more than a dozen collaboration agreements
 which provide for production of specific proteins. Additional information is
 available on GTC's web site, http://www.transgenics.com.
 
 

SOURCE Genzyme Transgenics Corporation
    FRAMINGHAM, Mass., April 17 /PRNewswire/ --
 Genzyme Transgenics (Nasdaq: GZTC) today said that its first quarter 2001
 financial results will be released on Friday, April 20, 2001, before the
 Nasdaq market opens.
     At 11:00 a.m. Eastern Time, as part of the Company's efforts to ensure
 full disclosure to all parties, Genzyme Transgenics will webcast a conference
 call with financial analysts live on the Company's internet site. This
 discussion is expected to include updates on the Company's many partnered
 programs. Dr. Sandra Nusinoff Lehrman, President and Chief Executive Officer,
 will lead the call. To access the live call or the archive, log onto
 http://www.transgenics.com. Please connect to the Company's website prior to
 the conference call to ensure adequate time for any software download that may
 be needed to hear the webcast.
     Genzyme Transgenics Corporation is a leader in developing medicines from
 the milk of specially bred animals, primarily goats. Many of the medicines
 under development are monoclonal antibodies and immunoglobulin fusion
 proteins. To date, GTC has formed more than a dozen collaboration agreements
 which provide for production of specific proteins. Additional information is
 available on GTC's web site, http://www.transgenics.com.
 
 SOURCE  Genzyme Transgenics Corporation